This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Maroteaux-Lamy Syndrome (MPS VI)

ItemDetails
A. Classification codesICD-10: E76.2 | Special Copayment Reduction: V117 | Coverage period: 5 years
B. SynonymsMaroteaux-Lamy syndrome (mild) (severe), mucopolysaccharidosis type VI, MPS VI, arylsulfatase B deficiency
C. Adult onsetLikelihood of first onset in adulthood low — symptoms appear at 2–3 years of age and diagnosis is made in childhood; in the attenuated form, diagnosis may be delayed until adolescence or adulthood, and intelligence is preserved as normal
SectionSummary
1. History1963, first described by Maroteaux and Lamy. 1984, identification of the ARSB gene. 2005, FDA approval of galsulfase (Naglazyme) opens the ERT era.
2. CausesArylsulfatase B (N-acetylgalactosamine-4-sulfatase) deficiency due to ARSB gene mutations. Lysosomal accumulation of dermatan sulfate and chondroitin-4-sulfate.
3. GeneticsARSB gene located at 5q14.1 on chromosome 5. Autosomal recessive inheritance. More than 130 pathogenic variants reported. The I505S variant is highly frequent in some populations.
4. General epidemiologyAbout 0.07–0.66 per 100,000 births. Relatively high frequency in some regions of Brazil. No sex difference.
5. PathophysiologyARSB deficiency → lysosomal accumulation of DS and C4S → damage to cartilage, bone, heart valves, cornea, and airway tissues → progression of multiorgan complications. No direct brain involvement.
6. SymptomsCoarse facies, short stature, joint contractures, corneal opacity (95%), heart valve abnormalities, airway obstruction. Intelligence normal. Divided into mild and severe forms by severity.
7. SignsHepatosplenomegaly, thoracolumbar kyphosis, oar-shaped rib deformity, corneal opacity, heart murmur, hydrocephalus. Confirmed by increased urine DS.
8. ScreeningQualitative and quantitative urine GAG testing (DS predominant), DBS-based ARSB enzyme activity measurement. Stepwise diagnosis when clinically suspected.
9. DiagnosisMeasurement of leukocyte ARSB enzyme activity is the gold standard. Confirmed by ARSB gene analysis. Multiple sulfatase deficiency must be excluded.
10. TreatmentGalsulfase (Naglazyme) ERT given intravenously once weekly is standard. ERT has limited effect on skeletal abnormalities; spinal surgery, cardiac surgery, corneal transplantation, etc. performed in parallel.
11. PrognosisIn the severe form, death from cardiopulmonary failure in the 2nd–4th decades. Long-term ERT stabilizes pulmonary and cardiac function and prolongs survival. Better prognosis in the attenuated form.
12. PreventionGenetic counseling, carrier testing (ARSB gene analysis), prenatal and preimplantation genetic diagnosis, efforts to expand newborn screening.
13. References10 recent references (with PMID/DOI)

1. History

Maroteaux-Lamy syndrome (MPS VI) was first described as a distinct disease in 1963 when the French pediatricians Pierre Maroteaux and Maurice Lamy presented pediatric cases with coarse facies, dwarfism, and severe skeletal abnormalities but normal intelligence. At the time it was clinically similar to Hurler syndrome but distinguished by preserved cognitive function, and it was named Maroteaux-Lamy syndrome after its two discoverers.

As the biochemistry of lysosomal storage diseases was elucidated through the 1970s and 80s, Fluharty et al. in 1984 identified arylsulfatase B (ARSB; official name: N-acetylgalactosamine-4-sulfatase), encoded by the ARSB gene, as the deficient enzyme. In 1992 the ARSB gene was cloned at 5q14.1 on chromosome 5, laying the foundation for molecular diagnosis. More than 130 pathogenic variants have since been reported, and high frequencies of specific variants due to founder effects have been confirmed in certain populations such as in Brazil.

In the history of treatment, galsulfase (Naglazyme; BioMarin Pharmaceutical) received FDA approval in 2005, introducing the first ERT for MPS VI into clinical practice. Randomized controlled trials demonstrated improvement in 6-minute walk distance and stair-climbing ability, and long-term follow-up studies reported stabilization of lung function and prolonged survival. Currently, optimization of the long-term effects of ERT, additional treatment strategies for skeletal abnormalities (gene therapy, substrate reduction therapy), and improved approaches to cardiac surgery are being actively studied.

2. Causes

The direct cause of MPS VI is deficiency or markedly reduced activity of the enzyme arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) due to ARSB gene mutations. ARSB is a sulfatase that removes the sulfate group from N-acetylgalactosamine-4-sulfate residues during the degradation of dermatan sulfate (DS) and chondroitin-4-sulfate (C4S).

When ARSB is deficient, DS and C4S progressively accumulate in lysosomes. Because DS is abundantly distributed mainly in connective tissue, cartilage, skin, heart valves, and cornea, GAG accumulation in MPS VI is prominent in these tissues. C4S is also abundant in cartilage and bone and contributes to skeletal abnormalities. Unlike MPS I and II, MPS VI has no heparan sulfate (HS) accumulation, so there is no direct central nervous system involvement and cognitive function is preserved. This is the key clinical difference between MPS VI and the severe forms of MPS I and II.

The degree of residual ARSB activity is the main factor determining the severity of the clinical phenotype. Very low residual activity produces the severe form, and partly preserved activity produces the attenuated form. Following GAG accumulation, secondary inflammatory responses, oxidative stress, apoptosis, and similar processes intensify tissue damage.

3. Genetics

The ARSB gene is located at position 14.1 on the long arm of chromosome 5 (5q14.1) and consists of 8 exons. The encoded ARSB protein (arylsulfatase B) is a lysosomal sulfatase of 533 amino acids and requires a post-translational modification in which a specific cysteine residue is converted to formylglycine for activation.

More than 130 pathogenic variants have been reported to date; by type, missense variants are the most common, and nonsense variants, splicing variants, and small insertions/deletions are included. Among the characteristic variants reported in MPS VI patients, I505S (p.Ile505Ser) shows high frequency due to a founder effect in northeastern Brazil and some Mediterranean populations. Variants associated with the severe phenotype are mainly complete loss-of-function variants (nonsense, large deletions), and the attenuated phenotype is associated with missense variants in which residual activity is preserved.

MPS VI is inherited in an autosomal recessive manner, and patients carry pathogenic variants in both ARSB alleles. Each parent is an asymptomatic carrier of one pathogenic variant. The carrier frequency is estimated at about 1/100–1/300. The genotype-phenotype correlation is not complete, but homozygous loss-of-function variants (null variants) are mostly associated with the severe phenotype. In compound heterozygotes, the phenotype is predicted by combining the residual activity of the two variants.

4. General epidemiology

The worldwide birth prevalence of MPS VI is reported as about 0.07–0.66 per 100,000 births, varying considerably by region and ethnicity. By country, about 1/43,000 has been reported in Australia, 1/1,500,000 in the Netherlands, and 1/193,000 in Portugal. In some regions of Brazil (e.g., the northeast), a relatively high frequency is observed due to a founder effect, explained by the high frequency of the I505S variant.

There is no difference in occurrence by sex (autosomal recessive inheritance). In Korea, national prevalence data are lacking, but the number of patients is being tracked through Special Copayment Reduction registration. Worldwide, MPS VI patients are estimated to number in the hundreds to thousands, and in countries with rare disease designation, orphan drug status has been granted, improving access to ERT. Data on natural history and treatment effects continue to accumulate through BioMarin's international patient registry (MPS VI registry).

5. Pathophysiology

The core pathogenesis of MPS VI is progressive lysosomal accumulation of dermatan sulfate (DS) and chondroitin-4-sulfate (C4S) due to ARSB enzyme deficiency. DS is a GAG composed of repeating disulfated disaccharide units of N-acetylgalactosamine-4-sulfate and iduronic acid, abundantly distributed in connective tissue, heart valve interstitial cells, skin fibroblasts, corneal stromal cells, cartilage, and vessel walls. C4S is abundant in the extracellular matrix of cartilage and bone.

DS accumulation in heart valve interstitial cells causes valve cell activation, hyperproliferation, and basement membrane thickening, leading to thickening and regurgitation or stenosis of the mitral, aortic, and tricuspid valves. DS deposition in corneal stromal cells causes corneal opacity and reduced vision, and MPS VI is known to have a very high frequency of corneal opacity (about 95%). In cartilage and the skeletal system, C4S and DS accumulation causes abnormal skeletal growth, dysostosis multiplex, and joint contractures.

In the airway, DS deposition in soft tissues and tracheal and bronchial cartilage causes airway obstruction and sleep apnea. In the liver, GAG deposition in hepatocytes and Kupffer cells causes hepatosplenomegaly. Central nervous system involvement is generally absent, so cognitive function is preserved as normal. As secondary pathological mechanisms, disruption of TGF-β and FGF signaling by DS accumulation, activation of inflammatory responses, and increased oxidative stress intensify tissue damage.

ERT (galsulfase) is taken up into cells via the lysosomal M6P receptor and restores GAG degradation, and intravenous administration is effective in reducing the GAG burden of most visceral organs and soft tissues. However, because ERT's access to GAG accumulation in cartilage and bone is limited, there are limits to improvement of skeletal lesions, and this is a major challenge for developing additional treatment strategies.

6. Symptoms

Patients with MPS VI are generally normal at birth, and symptoms begin to appear at around 2–3 years of age. The clinical phenotype is divided into the severe form and the attenuated form. In the severe form, symptoms progress early and rapidly; in the attenuated form, clinical symptoms appear later and progress more slowly. A characteristic feature is that intelligence is preserved as normal in all patients with MPS VI.

The main symptoms are as follows:

In the attenuated form, symptoms are mild and diagnosis is sometimes made in adolescence or adulthood. Because symptoms appear late and progress slowly, there may be adult patients with the attenuated form who are living undiagnosed.

7. Signs

On physical examination, coarse facies, a short neck, and thoracolumbar kyphosis are characteristically observed. In the eyes, corneal opacity is seen as diffuse clouding on slit-lamp examination, and its frequency is particularly high in MPS VI (about 95%). Glaucoma may also accompany reduced vision, so regular ophthalmologic examinations are needed. Retinal lesions are sometimes identified on fundus examination.

Abdominal examination reveals hepatosplenomegaly. Liver and spleen enlargement can be measured on abdominal ultrasound. Joint examination shows multiple joint contractures, and finger contractures (claw hand) are characteristic. Chest radiographs show oar-shaped rib deformity, and spinal radiographs show thoracolumbar hook vertebrae and abnormal vertebral body formation. Hand radiographs show metacarpals with widened bases and dysplasia of the carpal bones.

Valve murmurs may be heard on cardiac auscultation, and echocardiography shows thickening, regurgitation, or stenosis of the mitral, aortic, and tricuspid valves. Myocardial hypertrophy and cardiomyopathy may also be present. Neurological examination shows findings of carpal tunnel syndrome (positive Tinel and Phalen signs) and, in some patients, signs of raised intracranial pressure due to hydrocephalus. Brain MRI may show a 'J-shaped sella', ventricular enlargement, and meningeal thickening. On urine GAG electrophoresis the DS band is clearly increased, and on urine GAG quantification the creatinine-corrected DS value is increased above the age reference. Hearing tests show conductive and mixed hearing loss.

8. Screening

Screening for MPS VI begins with clinical suspicion. MPS VI should be included in the differential diagnosis in children with coarse facies, dwarfism, joint contractures, corneal opacity, a heart murmur, and normal intelligence. The main screening methods are as follows.

Urine GAG testing is the most basic screening tool. The qualitative Toluidine blue spot test or Berry spot test is simple and inexpensive but has a false-negative rate. Quantitative urine GAG measurement (creatinine-corrected) and electrophoresis to confirm a pattern of increased DS are more sensitive. MPS VI shows a characteristic pattern of predominantly increased DS bands, which allows further differentiation among DS-predominant MPS types (MPS I, II, VI).

Dried blood spot (DBS)-based ARSB enzyme activity measurement can be used for both newborn screening and clinical diagnosis. In some countries, ARSB is included in multiplex enzyme panel screening for lysosomal storage diseases. In Korea, MPS VI is not included among national newborn screening items, but stepwise diagnosis (urine GAG → enzyme activity → genetic analysis) is possible in patients with clinically suspicious symptoms. In newborns with a family history, early diagnosis is possible by ARSB gene analysis immediately after birth.

9. Diagnosis

MPS VI is confirmed by ARSB enzyme activity measurement and ARSB gene analysis.

Clinical evaluation

The combination of coarse facies, dwarfism, joint contractures, corneal opacity, heart valve abnormalities, and normal intelligence strongly suggests MPS VI. Radiographic findings (dysostosis multiplex, hook vertebra, oar-shaped ribs) also provide important evidence for diagnosis. Unlike MPS I, preserved cognitive function is a point of clinical differentiation.

Biochemical tests

A predominant increase in DS is confirmed by urine GAG quantification (creatinine-corrected) and electrophoresis. ARSB enzyme activity is measured in leukocytes or skin fibroblasts by a fluorescent substrate method (based on 4-methylumbelliferyl sulfate) or LC-MS/MS. Less than 10% of normal controls strongly suggests MPS VI. The activity of other sulfatases similar to the ARSB substrate (e.g., arylsulfatase A) must also be measured simultaneously to rule out multiple sulfatase deficiency.

Molecular genetic testing

Pathogenic variants are identified by sequencing all exons and adjacent intronic sequences of the ARSB gene (Sanger or NGS). Large deletions are confirmed by MLPA or aCGH. Genotype information is used for phenotype prediction (severe vs attenuated), identification of carriers in the family, and prenatal diagnosis. The differential diagnosis includes MPS I, MPS IV, multiple sulfatase deficiency, mucolipidosis II/III, mannosidosis, and others, which can be differentiated by the urine GAG electrophoresis pattern and enzyme activity results.

10. Treatment

Treatment of MPS VI combines disease-modifying treatment centered on galsulfase ERT with multidisciplinary symptomatic and surgical treatment.

Enzyme replacement therapy (ERT)

Galsulfase (Naglazyme; BioMarin Pharmaceutical) is a recombinant human ARSB approved by the FDA in 2005 and the EMA in 2006. It is given intravenously at 1 mg/kg once a week over about 4 hours. Randomized double-blind clinical trials demonstrated significant improvement in 12-minute walk distance and stair-climbing ability. Long-term follow-up studies (10 years or more) reported stabilization of lung function, stabilization of cardiac function, and prolonged survival. It also contributes to reduction of hepatosplenomegaly and urine GAG and improvement of joint range of motion. However, because the effect of ERT on the skeletal system (spinal deformity, joint contractures) is limited, combination with orthopedic surgery is important. Because hypersensitivity reactions may occur, antihistamine premedication and monitoring during infusion are needed.

Surgical treatment

As needed, orthopedic correction of spinal deformity (thoracolumbar kyphosis, scoliosis), valve replacement or repair when heart valve dysfunction has progressed, corneal transplantation for reduced vision due to corneal opacity, cerebrospinal fluid shunting for hydrocephalus, carpal tunnel decompression, and other procedures are performed. Particular care is required for airway management and anesthesia during surgery, and because the risk of airway obstruction is high, collaboration with an experienced anesthesiology team is essential.

Multidisciplinary symptomatic treatment

Includes positive airway pressure for sleep apnea, management of recurrent otitis media with tympanostomy tube insertion, hearing aids (mixed hearing loss), intraocular pressure control and regular ophthalmologic follow-up, regular cardiac monitoring (echocardiography at least once a year), physical, occupational, and speech therapy, and training in assistive devices for short stature.

Research on new treatments

AAV-based gene therapy, substrate reduction therapy, bone-targeted ERT, and gene-enhanced transplantation using hematopoietic stem cells are at the preclinical and early clinical trial stages. In particular, developing more effective approaches to skeletal lesions is a major goal of MPS VI treatment research.

11. Prognosis

The prognosis of MPS VI depends greatly on clinical severity and whether treatment is given. When the severe form follows its natural course without ERT, death often occurs before the 20s–30s (2nd–3rd decade) due to progression of cardiopulmonary failure, airway obstruction, and heart valve dysfunction. Heart valve abnormalities develop in almost all patients, worsen over time, and become a major cause of heart failure.

Long-term administration (10 years or more) of galsulfase ERT has been reported to contribute to stabilization of lung function, stabilization of cardiac function, and maintenance of walking ability, and to prolong survival. Ten-year follow-up results of the BioMarin-sponsored MPS VI registry study confirmed improved survival and clinical benefit in ERT-treated patients. However, because ERT cannot reverse skeletal deformities or structural heart valve abnormalities that have already progressed, early initiation of treatment is important for minimizing complications.

In the attenuated form, symptoms progress slowly and many patients survive beyond adulthood. Some patients have been reported to survive into their 40s–50s or older. Preservation of normal cognitive function is a prognostic advantage of MPS VI, and with appropriate treatment and management, education, work, and social participation are possible. However, cumulative complications such as joint contractures, reduced vision, cardiac complications, and hearing loss affect quality of life.

12. Prevention

Because MPS VI is an autosomal recessive genetic disease, prevention strategies center on genetic counseling, carrier testing, and prenatal and preimplantation genetic diagnosis. In genetic counseling, the family of a child with MPS VI is informed of the autosomal recessive mode of inheritance and the recurrence risk (25%), and carrier status is confirmed by ARSB gene analysis of both parents. Because enzyme activity measurement alone is insufficient for carrier identification, molecular genetic testing is essential.

Prenatal diagnosis is performed by fetal ARSB enzyme activity measurement and ARSB gene analysis through CVS (chorionic villus sampling) at 10–12 weeks of gestation or amniocentesis at 15–18 weeks. Preimplantation genetic testing (PGT-M) is a method in which embryos not carrying the pathogenic variant are selected and transferred for carrier couples who choose IVF, allowing prevention without termination of pregnancy. Early testing of the patient's siblings is also recommended, with genetic counseling provided after carrier status is determined.

Introduction of newborn screening is important for secondary prevention. It is based on the hypothesis that starting ERT before symptom onset through early diagnosis can minimize the progression of irreversible complications such as skeletal deformity, heart valve abnormalities, and corneal opacity. In newborn screening studies in some countries, ARSB is included in multiplex enzyme panels, and in Korea discussions are also under way on expanding newborn screening items for lysosomal storage diseases.

13. References

  1. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148(4):533-539. PMID: 16647419
  2. Giugliani R, Lampe C, Guffon N, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) — 10 year follow-up of patients who previously participated in an MPS VI Survey Study. Mol Genet Metab. 2014;111(3):445-450. PMID: 24360710
  3. Brands MM, Frohn-Mulder IM, Hagemans ML, et al. Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI. J Inherit Metab Dis. 2013;36(2):227-234. PMID: 22576887
  4. Furujo M, Kubo T, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol Genet Metab. 2011;104(4):597-602. PMID: 21855369
  5. Hendriksz CJ, Giugliani R, Harmatz P, et al. Multi-domain impact of enzyme replacement therapy with galsulfase in patients with mucopolysaccharidosis VI. Mol Genet Metab. 2015;114(2):178-185. PMID: 25559511
  6. Tomanin R, Zanetti A, Gualdi V, et al. The ARSB gene, encoding arylsulfatase B, is differentially expressed in human lens epithelial cells and trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52(1):337-342. PMID: 20926816
  7. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5:5. PMID: 20156360
  8. Maroteaux P, Lamy M, Foucher M. La maladie de Morquio. Etude clinique, radiologique et biologique. Presse Med. 1963;71:2091-2094.
  9. Azevedo AC, Schwartz IV, Kalakun L, et al. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet. 2004;66(3):208-213. PMID: 15324319
  10. Harmatz P, Cattaneo F, Bhatt A, et al. Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): long-term experience with galsulfase. Mol Genet Metab Rep. 2020;24:100608. DOI: 10.1016/j.ymgmr.2020.100608